Apellis shares are trading higher after the company said events of retinal vasculitis in treatment with SYFOVRE were rare, with an estimated real-world rate of 0.01% per injection.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals announced that events of retinal vasculitis in treatment with SYFOVRE were rare, with an estimated real-world rate of 0.01% per injection. This news has led to a rise in the company's stock.
August 22, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals' shares are trading higher after the company reported rare cases of retinal vasculitis with SYFOVRE treatment.
The announcement of rare cases of retinal vasculitis with SYFOVRE treatment is positive news for Apellis Pharmaceuticals. This indicates the safety and effectiveness of their product, which can boost investor confidence and lead to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100